Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome

Lancet Neurology

Volumn 5, Issue 10, 2006, Pages 878-886

  Paulus, Walter ^a   Trenkwalder, Claudia ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Centre of Parkinsonism and Movement Disorders   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; APOMORPHINE; AUTORECEPTOR; BENSERAZIDE PLUS LEVODOPA; CABERGOLINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IRON; LEVODOPA; OPIATE; QUINPIROLE;

ARTICLE; AUTOREGULATION; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG EFFECT; HUMAN; IRON DEFICIENCY; IRON THERAPY; LIMB MOVEMENT; LOW DRUG DOSE; MOTOR DYSFUNCTION; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; RESTLESS LEGS SYNDROME; SPINAL CORD STIMULATION; UNSPECIFIED SIDE EFFECT; PHYSIOLOGY; REVIEW;

CIRCADIAN RHYTHM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; HUMANS; IRON; LEVODOPA; RECEPTORS, DOPAMINE D2; RESTLESS LEGS SYNDROME;

EID: 33750594781     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70576-2     Document Type: Note

References (89)

1. Allen R., Picchietti D., Hening W., Trenkwalder C., Walters A., and Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4 (2003) 101-119
2. Walters A. Toward a better definition of the restless legs syndrome: the International Restless Legs Syndrome Study Group. Mov Disord 10 (1995) 634-642
3. Vetrugno R., Contin M., Baruzzi A., Provini F., Plazzi G., and Montagna P. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome. Mov Disord 21 (2006) 254-258
4. Allen R., and Earley C. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19 (1996) 205-213
5. Trenkwalder C., Collado Seidel V., Kazenwadel J., et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?. Mov Disord 18 (2003) 1184-1189
6. Winkelman J., and Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 5 (2004) 9-14
7. Ossipov M., Lai J., King T., Vanderah T., and Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 80 (2005) 319-324
8. Diener H., and Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 3 (2004) 475-483
9. Goldman-Rakic P., Muly III E., and Williams G. D1 receptors in prefrontal cells and circuits. Brain Res Rev 31 (2000) 295-301
10. Wetter T., Eisensehr I., and Trenkwalder C. Functional neuroimaging studies in restless legs syndrome. Sleep Med 5 (2004) 401-406
11. Cervenka S., Palhagen S., Comley R., et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 129 (2006) 2017-2028
12. Trenkwalder C., and Paulus W. Why do restless legs occur at rest?-pathophysiology of neuronal structures in RLS: neurophysiology of RLS (part 2). Clin Neurophysiol 115 (2004) 1975-1988
13. Ondo W., He Y., Rajasekaran S., and Le W. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 15 (2000) 154-158
14. Trenkwalder C., Paulus W., and Walters A. The restless legs syndrome. Lancet Neurol 4 (2005) 465-475
15. Winkelmann J., Lichtner P., Putz B., et al. Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome. Mov Disord 21 (2006) 28-33
16. Desautels A., Turecki G., Montplaisir J., et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 62 (2005) 591-596
17. Desautels A., Turecki G., Montplaisir J., et al. Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. Neurology 59 (2002) 215-219
18. Adel S., Djarmati A., Kabakci K., et al. Co-occurrence of restless legs syndrome and Parkin mutations in two families. Mov Disord 21 (2006) 258-263
19. Kaiser R., Hofer A., Grapengiesser A., et al. L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60 (2003) 1750-1755
20. Kirchheiner J., Nickchen K., Bauer M., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9 (2004) 442-473
21. Millan M. Descending control of pain. Prog Neurobiol 66 (2002) 355-474
22. Barriere G., Cazalets J., Bioulac B., Tison F., and Ghorayeb I. The restless legs syndrome. Prog Neurobiol 77 (2005) 139-165
23. Noga B., Pinzon A., Mesigil R., and Hentall I. Steady-state levels of monoamines in the rat lumbar spinal cord: spatial mapping and the effect of acute spinal cord injury. J Neurophysiol 92 (2004) 567-577
24. Holstege J., Van Dijken H., Buijs R., Goedknegt H., Gosens T., and Bongers C. Distribution of dopamine immunoreactivity in the rat, cat and monkey spinal cord. J Comp Neurol 376 (1996) 631-652
25. Ridet J., Sandillon F., Rajaofetra N., Geffard M., and Privat A. Spinal dopaminergic system of the rat: light and electron microscopic study using an antiserum against dopamine, with particular emphasis on synaptic incidence. Brain Res 598 (1992) 233-241
26. Fleetwood-Walker S., Hope P., and Mitchell R. Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. J Physiol 399 (1988) 335-348
27. Clemens S., Rye D., and Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 67 (2006) 125-130
28. Goldstein D., Eisenhofer G., and Kopin I. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 305 (2003) 800-811
29. Schmitz Y., Benoit-Marand M., Gonon F., and Sulzer D. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 87 (2003) 273-289
30. Pothos E., Sulzer D., and Hoebel B. Plasticity of quantal size in ventral midbrain dopamine neurons: possible implications for the neurochemistry of feeding and reward. Appetite 31 (1998) 405
31. Pothos E., Mosharov E., Liu K., et al. Stimulation-dependent regulation of the pH, volume and quantal size of bovine and rodent secretory vesicles. J Physiol 542 (2002) 453-476
32. Pothos E., Davila V., and Sulzer D. Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. J Neurosci 18 (1998) 4106-4118
33. Zhao W., Latinwo L., Liu X., Lee E., Lamango N., and Charlton C. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. Exp Neurol 171 (2001) 127-138
34. Venugopalan V., Ghali Z., Senecal J., Reader T., and Descarries L. Catecholaminergic activation of G-protein coupling in rat spinal cord: further evidence for the existence of dopamine and noradrenaline receptors in spinal grey and white matter. Brain Res 1070 (2006) 90-100
35. Yang H., Zhou L., Hu N., Xin W., and Liu X. Activation of spinal d1/d5 receptors induces late-phase LTP of C-fiber-evoked field potentials in rat spinal dorsal horn. J Neurophysiol 94 (2005) 961-967
36. Missale C., Nash S., Robinson S., Jaber M., and Caron M. Dopamine receptors: from structure to function. Physiol Rev 78 (1998) 189-225
37. Van Hartesveldt C. Temporal and environmental effects on quinpirole-induced biphasic locomotion in rats. Pharmacol Biochem Behav 58 (1997) 955-960
38. Zhuang X., Oosting R., Jones S., et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 98 (2001) 1982-1987
39. Barik S., and de Beaurepaire R. Hypothermic effects of dopamine D3 receptor agonists in the island of Calleja Magna. Potentiation by D1 activation. Pharmacol Biochem Behav 60 (1998) 313-319
40. Paulus W., and Schomburg E. Dopamine and the spinal cord in Restless Legs Syndrome: Does spinal cord physiology reveal a basis of augmentation?. Sleep Med Rev 10 (2006) 185-196
41. Lomanowska A., Gormley S., and Szechtman H. Presynaptic stimulation and development of locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 77 (2004) 617-622
42. Mercuri N., Saiardi A., Bonci A., et al. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 79 (1997) 323-327
43. de la Fuente-Fernandez R., Schulzer M., Mak E., Calne D., and Stoessl A. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 127 (2004) 888-899
44. L'Hirondel M., Cheramy A., Godeheu G., et al. Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice. Brain Res 792 (1998) 253-262
45. Hessler N., Shirke A., and Malinow R. The probability of transmitter release at a mammalian central synapse. Nature 366 (1993) 569-572
46. Goda Y., and Stevens C. Two components of transmitter release at a central synapse. Proc Natl Acad Sci USA 91 (1994) 12942-12946
47. Sudhof T. The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature 375 (1995) 645-653
48. Komendantov A., Komendantova O., Johnson S., and Canavier C. A Modeling Study Suggests Complementary Roles for GABAA and NMDA Receptors and the SK Channel in Regulating the Firing Pattern in Midbrain Dopamine Neurons. J Neurophysiol 91 (2004) 346-357
49. Floresco S., West A., Ash B., Moore H., and Grace A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6 (2003) 968-973
50. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 80 (1998) 1-27
51. Sulzer D., and Galli A. Dopamine transport currents are promoted from curiosity to physiology. Trends Neurosci 26 (2003) 173-176
52. Garris P., Ciolkowski E., Pastore P., and Wightman R. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14 (1994) 6084-6093
53. Chergui K., Suaud-Chagny M., and Gonon F. Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. Neuroscience 62 (1994) 641-645
54. Beckstead M., Grandy D., Wickman K., and Williams J. Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons. Neuron 42 (2004) 939-946
55. Ross S. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem 56 (1991) 22-29
56. Borowsky B., and Hoffman B. Neurotransmitter transporters: molecular biology, function, and regulation. Int Rev Neurobiol 38 (1995) 139-199
57. Kimmel H., Joyce A., Carroll F., and Kuhar M. Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. J Pharmacol Exp Ther 298 (2001) 129-140
58. Cragg S., and Rice M. DAncing past the DAT at a DA synapse. Trends Neurosci 27 (2004) 270-277
59. Jones S., Gainetdinov R., Jaber M., Giros B., Wightman R., and Caron M. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95 (1998) 4029-4034
60. Jeziorski M., and White F. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors. Synapse 4 (1989) 267-280
61. Clemens S., Sawchuk M., and Hochman S. Reversal of the circadian expression of tyrosine-hydroxylase but not nitric oxide synthase levels in the spinal cord of dopamine D(3) receptor knockout mice. Neuroscience 133 (2005) 353-357
62. Gainetdinov R., Jones S., and Caron M. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol Psychiatry 46 (1999) 303-311
63. Clemens S., and Hochman S. Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24 (2004) 11337-11345
64. Levant B., and McCarson K. D(3) dopamine receptors in rat spinal cord: implications for sensory and motor function. Neurosci Lett 303 (2001) 9-12
65. Gerlach M., Double K., Arzberger T., Leblhuber F., Tatschner T., and Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110 (2003) 1119-1127
66. Bartlett S., Enquist J., Hopf F., et al. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA 102 (2005) 11521-11526
67. Chen J., Aloyo V., and Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience 54 (1993) 669-680
68. Eckbom K. Restless legs: a clinical study. Acta Med Scand (suppl) 159 (1945) 1-122
69. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 5 (2004) 385-391
70. Allen R. Iron, RLS and blood donations. Sleep Med 5 (2004) 113-114
71. Beard J., and Connor J. Iron status and neural functioning. Ann Rev Nutr 23 (2003) 41-58
72. Burhans M., Dailey C., Beard Z., et al. Iron deficiency: differential effects on monoamine transporters. Nutr Neurosci 8 (2005) 31-38
73. Erikson K., Jones B., and Beard J. Iron deficiency alters dopamine transporter functioning in rat striatum. J Nutr 130 (2000) 2831-2837
74. Erikson K., Jones B., Hess E., Zhang Q., and Beard J. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav 69 (2001) 409-418
75. Wang X., Wiesinger J., Beard J., et al. Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome. J Neurol Sci 220 (2004) 59-66
76. Connor J., Boyer P., Menzies S., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 61 (2003) 304-309
77. Earley C., Heckler D., and Allen R. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 5 (2004) 231-235
78. Sloand J., Shelly M., Feigin A., Bernstein P., and Monk R. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 43 (2004) 663-670
79. Davis B., Rajput A., Rajput M., Aul E., and Eichhorn G. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 43 (2000) 70-75
80. Earley C., Heckler D., and Allen R. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med 6 (2005) 301-305
81. Ondo W., Vuong K., and Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59 (2002) 421-424
82. Michaud M., Dumont M., Selmaoui B., Paquet J., Fantini M., and Montplaisir J. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol 55 (2004) 372-380
83. Weber M., Lauterburg T., Tobler I., and Burgunder J. Circadian patterns of neurotransmitter related gene expression in motor regions of the rat brain. Neurosci Lett 358 (2004) 17-20
84. Nunes Junior G., Tufik S., and Nobrega J. Autoradiographic analysis of D1 and D2 dopaminergic receptors in rat brain after paradoxical sleep deprivation. Brain Res Bull 34 (1994) 453-456
85. Serra G., Melis M., Argiolas A., Fadda F., and Gessa G. REM sleep deprivation induces subsensitivity of dopamine receptors mediating sedation in rats. Eur J Pharmacol 72 (1981) 131-135
86. Tufik S., Lindsey C., and Carlini E. Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain?. Pharmacology 16 (1978) 98-105
87. Seamans J., and Yang C. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74 (2004) 1-58
88. Usiello A., Baik J., Rouge-Pont F., et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408 (2000) 199-203
89. Lopez A., Munoz A., Guerra M., and Labandeira-Garcia J. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 103 (2001) 639-651